Ariel Precision Medicine

Ariel Precision Medicine develops precision medicine solutions that integrate advanced genetics with AI-driven analytics to diagnose complex chronic diseases—primarily focusing on pancreatitis—and guide personalized treatment strategies. Their lead drug candidate APM‑176 targets a defective protein implicated in pancreatitis and is phase II ready. The company’s ADVANCE® platform enables deep patient stratification by combining genetic data with environmental/lifestyle factors to inform both diagnosis and therapeutic development. No approved therapeutics exist yet for pancreatitis; their approach aims to address this unmet need by mapping disease subtypes at the molecular level.